App-Quantinova.ai

Feasibility of finding circulating tumors cells and assigning PD-L1 receptor status using single-cell technology combined with Celsee Genesis system.

Shaheen Riadh Alanee - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF): Results of a planned interim analysis.

Loic Mourey - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Carboplatin

Biomarker analysis (CTC and ctDNA/RNA) of GT0918 (Proxalutamide) new AR blocker in phase I mCRPC patients with dose escalation.

Karl Zhou - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Docetaxel

Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial.

Paul Vincent Viscuse - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

CB-7598

Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.

Matthew Raymond Smith - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

Alkaline phosphatase

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

Johann S. De Bono - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metastatic castration-resistant prostate cancer

CB-7598

Association of very small nuclear circulating tumor cell (vsnCTC) with clinical outcomes in metastatic castration-resistant prostate cancer.

Jasmine Jiemei Wang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Predicting long-term results with circulating tumor cells in patients with de novo androgen sensitive prostate cancer treated with hTERT peptides vaccine.

Wolfgang Lilleby - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).

Santosh Gupta - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

N/A

AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.

Andrew J. Armstrong - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

taxane

Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).

Rahul Raj Aggarwal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Pembrolizumab

Gene expression in circulating tumor cells (CTC) and plasma androgen receptor (AR) gene copy number (CN) for castration-resistant prostate cancer (CRPC) patients (pts) treated with cabazitaxel.

Giorgia Gurioli - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Cabazitaxel

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

Landon Carter Brown - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Enzalutamide

Prostate cancer CTC-RNA Assay: A new method for contemporary genomics and precision medicine via liquid biopsy.

Pai-Chi Teng - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy.

Joshua Michael Lang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

IMMU132

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Dexamethasone

Chemokine signaling and MAPK/ERK pathway for advanced prostate cancer treatment response.

Yazan Numan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND CLONOGENIC TUMOR CELLS

Alejandra Leivas - European Hematology Association (EHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

IMMUNOLOGICAL RECONSTITUTION AND PLATELET DISFUNCTION DURING IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Idanna Innocenti - European Hematology Association (EHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ibrutinib

NIVOLUMAB IN COMBINATION WITH BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA AFTER FAILURE OF NIVOLUMAB MONOTHERAPY

Luibov Tsvetkova - European Hematology Association (EHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Adcetris

Filters

1671 Abstracts